None listed
Conditions
Brief summary
Efficacy and safety of a combination of propolis and N-Acetylcysteine (NAC); (PropoMucil 600 manufactured by Abela Pharm, Serbia) versus placebo in patients with asthma or COPD, and productive cough for a period of 10 days as measured by the amount of sputum, cough impact on the patient, parameters of inflammation (C-reactive protein, erythrocyte sedimentation rate).
Interventions
The study assessing the efficacy and safety of a combination of propolis and N-Acetylcysteine (PropoMucil 600, Abela Pharm; 80mg propolis+600mg NAC) versus placebo in patients with asthma or COPD or bronchitis, with productive cough, one sachet of powder (3g), once daily for a period of 10 days (sachet will be prepared prior to administration, each sachet dissolved in 125ml (1/4 pint) of water.). A prospective, randomized, double-blind, placebo-controlled study will include 100 consecutive patie
The study assessing the efficacy and safety of a combination of propolis and N-Acetylcysteine (PropoMucil 600, Abela Pharm; 80mg propolis+600mg NAC) versus placebo in patients with asthma or COPD or bronchitis, with productive cough, one sachet of powder (3g), once daily for a period of 10 days (sachet will be prepared prior to administration, each sachet dissolved in 125ml (1/4 pint) of water.). A prospective, randomized, double-blind, placebo-controlled study will include 100 consecutive patients. Empty, used, sachets must returned at the end of the treatment to the study site.
Sponsors
Abela Pharm
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects are between the age of 18 and 85 with acute exacerbation of chronic obstructive pulmonary disease (COPD), acute and chronic bronchitis or asthma who have chest symptoms such as cough and sputum production (particularly increased breathlessness and cough, and increased sputum), treating with conventional therapy (corticosteroid and antibiotics) 2. Gender: both males and females 3. Informed, written consent will be obtained from all respondents (patients)
Exclusion criteria
1. status asthmaticus 2. history of stomach or duodenal ulcer 3. <18 years of age 4. patients who are sensitive to NAC and propolis
Outcome results
None listed